Biobizkaia
Centre de recherche
Dokuz Eylül University
Esmirna, TurquíaPublications en collaboration avec des chercheurs de Dokuz Eylül University (14)
2023
-
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry
Neurodegenerative Disease Management, Vol. 13, Núm. 4, pp. 215-221
-
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713
-
Comparative effectiveness in multiple sclerosis: A methodological comparison
Multiple Sclerosis Journal, Vol. 29, Núm. 3, pp. 326-332
-
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
Multiple Sclerosis Journal, Vol. 29, Núm. 2, pp. 221-235
-
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis
European Journal of Neurology, Vol. 30, Núm. 4, pp. 1014-1024
2022
-
Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study
Neurology, Vol. 98, Núm. 24, pp. E2401-E2412
-
Confirmed disability progression as a marker of permanent disability in multiple sclerosis
European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334
-
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
Neurology, Vol. 99, Núm. 17, pp. E1926-E1944
2021
-
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis
Multiple Sclerosis Journal, Vol. 27, Núm. 5, pp. 755-766
-
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression
Computer Methods and Programs in Biomedicine, Vol. 208
2020
-
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Brain, Vol. 143, Núm. 9, pp. 2742-2756
-
Risk of secondary progressive multiple sclerosis: A longitudinal study
Multiple Sclerosis Journal, Vol. 26, Núm. 1, pp. 79-90
2019
-
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 90, Núm. 4, pp. 458-468